Pgc-1α Overexpression Downregulates Pitx3 and Increases Susceptibility to MPTP Toxicity Associated with Decreased Bdnf

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Clark, Joanne ^a   Silvaggi, Jessica M ^a   Kiselak, Tomas ^a   Zheng, Kangni ^a   Clore, Elizabeth L ^a   Dai, Ying ^a   Bass, Caroline E ^b   Simon, David K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR PITX3; TYROSINE 3 MONOOXYGENASE;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE DEPLETION; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC SUSCEPTIBILITY; IMMUNOREACTIVITY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PGC 1ALPHA GENE; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; DEPENDOVIRUS; DOPAMINE; DOPAMINERGIC NEURONS; DOWN-REGULATION; HOMEODOMAIN PROTEINS; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MPTP POISONING; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84868706935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048925     Document Type: Article

References (69)

1. Simon DK, MF Beal (2001) Pathogenesis: oxidative stress, mitochondrial dysfunction and excitotoxicity, in Parkinson's Disease: Diagnosis and Clinical Management, S.A. Factor and W.J. Weiner, Editors. Demos Vermande: New York. p. chapt 27.
2. Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: p. 120-31.
3. Schapira AH, Gegg M (2011) Mitochondrial Contribution to Parkinson's Disease Pathogenesis. Parkinson's Disease, 2011.
4. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol. 53 Suppl 3: p. S26-36; discussion S36-8.
5. Lin MT, MF Beal (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 443(7113): p. 787-95.
6. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 127(2): p. 397-408.
7. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M, et al. (2005) PGC-1{alpha} regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 66(3): p. 562-573.
8. Wullner U, Loschmann P-A, Schultz JB, Schmid A, Dringen R, et al. (1996) Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport. 7(4): p. 921-3.
9. Esterbauer H, Oberkofler H, Krempler F, Patsch W (1999) Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 62(1): p. 98-102.
10. Knutti D, A Kaul, Kralli A (2000) A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. Mol Cell Biol. 20(7): p. 2411-22.
11. Baar K, Wende AR, Jones TE, Marison M. Nolte LA, et al. (2002) Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional activator PGC-1. Faseb J. 16(14): p. 1879-86.
12. Pilegaard H, Saltin B, Neufer PD (2003) Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol. 546: p. 851-8.
13. Puigserver P, Wu Z, Park C-W, Graves R, Wright M, et al. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92(6): p. 829-39.
14. Wareski P, Vaarmaan A, Choubey V, Safiulina D, Liiv J, et al. (2009) PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem. 284(32): p. 21379-85.
15. Handschin C, Li P, Liu F, Maratos-Flier E, et al. (2007) Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J Biol Chem. 282(41): p. 30014-21.
16. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, et al. (2001) CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 413(6852): p. 179-83.
17. Czubryt MP, McAnally J, Fishman GI, Olson EN (2003) Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci U S A 100(4): p. 1711-6.
18. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 27(7): p. 728-35.
19. Wang L, Liu J, Saha P, Huang J, Chan L, et al. (2005) The orphan nuclear receptor SHP regulates PGC-1alpha expression and energy production in brown adipocytes. Cell Metab. 2(4): p. 227-38.
20. Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1(6): p. 361-70.
21. Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, et al. (2012) A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset. Hum Mol Genet. 21(15): p. 3461-3473.
22. Clark J, Simon DK (2008) Transcribe to Survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal, 2008.
23. Cui L, Jeong H, Borovecki E, Parkhurst CN, Tanese N, et al. (2006) Transcriptional Repression of PGC-1[alpha] by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration. Cell. 127(1): p. 59-69.
24. Zhao W, Varghese M, Yemul S, Pan Y, Cheng A, et al. (2011) Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1alpha) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis. Mol Neurodegener. 6(1): p. 51.
25. Liang H, Ward WF, Jang YC, Bhattacharya A, Bokov AF, et al. (2011) PGC-1alpha protects neurons and alters disease progression in an amyotrophic lateral sclerosis mouse model. Muscle Nerve. 44(6): p. 947-56.
26. Taherzadeh-Fard E, Saft C, Andrich J, Wieczorek S, Arning L (2009) PGC-1alpha as modifier of onset age in Huntington disease. Molecular Neurodegeneration. 4(1): p. 10.
27. Weydt P, Soyal S, Gellera C, DiDonato S, Weidinger C, et al. (2009) The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Molecular Neurodegeneration. 4(1): p. 3.
28. Helisalmi S, Vepsalainen S, Hiltunen M, Koivisto AM, Salminen A, et al. (2008) Genetic study between SIRT1, PPARD, PGC-1alpha genes and Alzheimer's disease. J Neurol. 255(5): p. 668-73.
29. Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet. 12: p. 69.
30. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2(52): p. 52ra73.
31. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392(6676): p. 605-8.
32. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, et al. (2000) Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med. 342(21): p. 1560-7.
33. Shin JH, Ko HS, Kang H, Lee Y, Lee Y-I, et al. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell. 144(5): p. 689-702.
34. Mudo G, Di Liberto V, Tselykh TV, Oliveri M, et al. (2012) Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci. 69(7): p. 1153-65.
35. Ciron B, Lengacher S, Dusonchet J, Aebischer P, Schneider BL (2012) Sustained expression of PGC-1alpha in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet. 21(8): p. 1861-76.
36. Lerin C, Rodgers JT, Kalume DE, Kim SH, Pandey A, et al. (2006) GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1[alpha]. Cell Metabolism. 3(6): p. 429-438.
37. Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 72(3): p. 2224-32.
38. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99(18): p. 11854-9.
39. De BP, Heguy A, Heckett N, Ferris B, Leopold P, et al. (2006) High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther. 13(1): p. 67-76.
40. Clark J, Clore EL, Zheng K, Adame A, Masliah E, et al. (2010) Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One. 5(8): p. e12333.
41. Zhang Y, Huypens P, Adamson AW, Chang JS, Henagan TM, et al. (2009) Alternative mRNA splicing produces a novel biologically active short isoform of PGC-1alpha. J Biol Chem. 284(47): p. 32813-26.
42. Peng C, Aron L, Klein R, Li M, Wurst W, et al. (2011) Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J Neurosci. 31(36): p. 12802-15.
43. Jacobs FM, van Erp S, van der Linden AJA, von Oerthel L, Burbach PH, et al. (2009) Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development. 136(4): p. 531-40.
44. Puigserver P, Spiegelman BM (2003) Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev. 24(1): p. 78-90.
45. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, et al. (2001) Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 8(5): p. 971-82.
46. Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, et al. (2008) SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis. Genes Dev. 22(2): p. 252-64.
47. Trausch-Azar J, Leone TC, Kelly DP, Schwartz AL (2010) Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1{alpha} via the N-terminal pathway. J Biol Chem. 285(51): p. 40192-200.
48. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, et al. (2004) Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res. 94(4): p. 525-33.
49. Miura S, Tomitsuke E, Yasutomi K, Yamazaki T, et al. (2006) Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP. Am J Pathol. 169(4): p. 1129-39.
50. Hyman C, Hofer M, Barde Y-M, Juhasz M, Yancopoulos GD, et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 350(6315): p. 230-2.
51. Loeliger MM, Briscoe T, Rees SM (2008) BDNF Increases Survival of Retinal Dopaminergic Neurons after Prenatal Compromise. Inv Ophthamol & Vis Sci. 49(3): p. 1282-1289.
52. Parain K, Murer MG, Yan Q, Faucheux B, Agid Y, et al. (1999) Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport. 10(3): p. 557-561.
53. Levivier M, Przedborski S, Bencsis C, Kang UJ (1995) Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci. 15(12): p. 7810-7820.
54. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, et al. (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A. 91(11): p. 5104-8.
55. Galpern WR, Frim DM, Tatter SB, Altar CA, Beal MF, et al. (1996) Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant. 5(2): p. 225-32.
56. Tsukahara T, Takeda M, Shimohama S, Ohara O, Hashimoto N (1995) Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys. Neurosurgery. 37(4): p. 733-741.
57. Wang ZH, Ji Y, Shan W, Zeng B, Raksadawan N, et al. (2002) Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease. Neuroscience. 113(3): p. 629-40.
58. van den Munckhof P, Luk KC, Ste-Marie, Montgomery J, Blanchet P, et al. (2003) Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development. 130(11): p. 2535-42.
59. Smidt MP, Smits SM, Burbach JP (2004) Homeobox gene Pitx3 and its role in the development of dopamine neurons of the substantia nigra. Cell Tissue Res. 318(1): p. 35-43.
60. Yang D, Peng C, Li X, Fan X, Li L, et al. (2008) Pitx3-transfected astrocytes secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures. J Neurosci Res. 86(15): p. 3393-400.
61. Lebel M, Gauthier Y, Moreau A, Drouin J (2001) Pitx3 activates mouse tyrosine hydroxylase promoter via a high-affinity binding site. J Neurochem. 77(2): p. 558-67.
62. Maxwell SL, Ho Y, Kuehner E, Zhao S, Lin M (2005) Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. Dev Biol. 282(2): p. 467-79.
63. Messmer K, Remington MP, Skidmore F, Fishman PS (2007) Induction of tyrosine hydroxylase expression by the transcription factor Pitx3. Int J Dev Neurosci. 25(1): p. 29-37.
64. Hwang DY, Hong DY, Jeong JW, Choi S, Kim H, et al. (2009) Vesicular monoamine transporter 2 and dopamine transporter are molecular targets of Pitx3 in the ventral midbrain dopamine neurons. J Neurochem. 111(5): p. 1202-12.
65. Fukuchi M, Fujii H, Takachi H, Ichinose H, Kuwane Y, et al. (2010) Activation of tyrosine hydroxylase (TH) gene transcription induced by brain-derived neurotrophic factor (BDNF) and its selective inhibition through Ca2+ signals evoked via the N-methyl-d-aspartate (NMDA) receptor. Brain Research. 1366(0): p. 18-26.
66. Daniels GM, Amara SG (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem. 274(50): p. 35794-801.
67. Doskeland AP, Flatmark T (2002) Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. Eur J Biochem. 269(5): p. 1561-9.
68. Nakashima A, Mori K, Kaneko YS, Hayashi N, Nagatsu T, et al. (2011) Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers proteasomal digestion of the enzyme. Biochem Biophys Res Commun. 407(2): p. 343-7.
69. Lindholm D, Ericksson O, Makela J, Belluardo N, Korhonen L (2012) PGC-1α: a master gene that is hard to master. Cell Mol Life Sci. 69: p. 2465-2468.